Dilara McCauley

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

Rosa Lapalombella, Qingxiang Sun, Katie Williams et al. · Blood · 2012 · 293 citations · Full text

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

Albiruni R. Abdul Razak, Morten Mau‐Sørensen, Nashat Gabrail et al. · Journal of Clinical Oncology · 2016 · 244 citations · Full text

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells

Julia Etchin, Qingxiang Sun, Alex Kentsis et al. · Leukemia · 2012 · 190 citations · Full text

<scp>KPT</scp>‐330 inhibitor of <scp>CRM</scp>1 (<scp>XPO</scp>1)‐mediated nuclear export has selective anti‐leukaemic activity in preclinical models of <scp>T</scp>‐cell acute lymphoblastic leukaemia and acute myeloid leukaemia

Julia Etchin, Takaomi Sanda, Marc R. Mansour et al. · British Journal of Haematology · 2013 · 173 citations · Full text

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

Jessica Schmidt, Esteban Braggio, K. Martin Kortuem et al. · Leukemia · 2013 · 161 citations

Hematological Malignancy, Genome-wide Studies, Oncology +8